Delving into the Latest Updates on Ethismos Research, Inc. with Synapse

概览

疾病领域	数量

神经系统疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

DAT x NET x SERT	1

关联

1

项与 Ethismos Research, Inc. 相关的药物

Amitifadine Hydrochloride

靶点

DAT x NET x SERT

作用机制

DAT拮抗剂 [+2]

在研机构

Ethismos Research, Inc.

原研机构

Euthymics Bioscience, Inc.

在研适应症

慢性肌肉骨骼疼痛 [+1]

非在研适应症

重度抑郁症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

100 项与 Ethismos Research, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Ethismos Research, Inc. 相关的专利（医药）

登录后查看更多信息

4

项与 Ethismos Research, Inc. 相关的文献（医药）

2021-04-01·Psychopharmacology

Correction to: Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats

作者: Blair, Graham ; Modarres, John ; Vierling, Alexander ; McKinney, Anthony ; Wells, Corinne ; Levin, Edward D ; Rezvani, Amir H ; Hawkey, Andrew ; Holloway, Zade ; Pace, Caroline ; Ko, Ashley ; Rose, Jed E

A Correction to this paper has been published: https://doi.org/10.1007/s00213-021-05794-y

2020-06-01·Psychopharmacology3区 · 医学

Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats

3区 · 医学

Article

作者: Blair, Graham ; Modarres, John ; Vierling, Alexander ; McKinney, Anthony ; Wells, Corinne ; Levin, Edward D ; Rezvani, Amir H ; Hawkey, Andrew ; Holloway, Zade ; Pace, Caroline ; Ko, Ashley ; Rose, Jed E

RATIONALEA variety of neural systems are involved in drug addiction, and some of these systems are shared across different addictive drugs. We have found several different types of drug treatments that successfully reduce nicotine self-administration.OBJECTIVESThe current set of studies is the first in a series to determine if drug treatments that have been found to significantly reduce nicotine self-administration would reduce opiate self-administration.METHODSAmitifadine, a triple reuptake inhibitor of dopamine, norepinephrine, and serotonin, was assessed in female Sprague-Dawley rats to determine whether it significantly reduces remifentanil self-administration with either acute or chronic treatment.RESULTSAcutely, amitifadine doses of 5, 10, and 20 mg/kg each significantly reduced remifentanil self-administration. In a chronic study, repeated treatment with 10 mg/kg of amitifadine continued to reduce remifentanil self-administration, even after the cessation of treatment. However, amitifadine was not found to attenuate the rise in remifentanil self-administration with continued access. This study and our earlier one showed that the 10 mg/kg amitifadine dose did not significantly affect food motivated responding. Amitifadine did not attenuate remifentanil-induced antinociception as measured on the hot plate test but extended and maintained antinociceptive effects.CONCLUSIONSThese studies show the promise of amitifadine as a treatment for countering opiate self-administration for adjunctive use with opioids for analgesia. Further studies are needed to determine the possible efficacy of amitifadine for combating opiate addiction or preventing it in humans during adjunctive use with opioids for chronic pain.

2020-02-06·Nicotine & Tobacco Research2区 · 医学

Prolonging the Reduction of Nicotine Self-Administration in Rats by Coadministering Chronic Nicotine With Amitifadine, a Triple Monoamine Reuptake Inhibitor With CYP2B6 Inhibitory Actions

2区 · 医学

Article

作者: Lee, Michelle ; Levin, Edward D ; Wells, Corinne ; Rose, Jed E ; Slade, Susan ; Rezvani, Amir H ; McKinney, Anthony A

AbstractIntroductionExisting treatments can aid tobacco smoking cessation, but they have low efficacy. Because there is a network of neural systems involved in tobacco addiction, combination treatments may provide greater efficacy. Chronic nicotine and amitifadine have each been shown to significantly reduce nicotine self-administration in rats. This study was conducted to determine if the combination of chronic nicotine with amitifadine, a triple monoamine reuptake inhibitor with CYP2B inhibitory effects, would reduce nicotine self-administration to a greater extent than either alone or placebo.MethodsThis study tested the combination of nicotine plus amitifadine in young adult female Sprague-Dawley rats self-administering nicotine (0.03 mg/kg/infusion). This combination was compared with each treatment alone and the vehicle during continuing nicotine self-administration as well as during resumption of self-administration after a week of enforced abstinence, modeling a quit attempt. Finally, we studied the residual effects of these therapies after discontinuation of treatment.ResultsTreatment with either chronic nicotine or amitifadine alone significantly reduced nicotine self-administration relative to controls. The combination of the treatments significantly enhanced this effect. After treatment withdrawal, all of the groups showed increases in nicotine self-administration, but only the combined treatment group remained significantly below control rates of nicotine self-administration.ConclusionsThis study showed the promise of amitifadine as a possible new treatment for smoking cessation and suggested that amitifadine is more effective when given with chronic nicotine. The improved efficacy of the amitifadine and nicotine combination may be potentiated by amitifadine’s inhibitory effects on CYP2B, which slows nicotine metabolism.ImplicationsThis study replicated the effects that chronic nicotine or chronic amitifadine, a triple reuptake inhibitor, significantly reduces nicotine self-administration in rats. It extends those findings by showing that the combination of chronic nicotine plus amitifadine causes significantly greater reduction in nicotine self-administration than either drug treatment alone. The combination of chronic amitifadine and chronic nicotine also causes a persistent significant reduction in nicotine self-administration after the end of treatment. The amitifadine and nicotine treatment should be assessed in humans to determine whether this combination provides greater efficacy in smoking cessation than transdermal nicotine treatment alone.

100 项与 Ethismos Research, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Ethismos Research, Inc. 相关的转化医学

登录后查看更多信息